Feixiang Wang
Impact in
-
- Urological Disorders and Treatments
-
- Cancer-related molecular mechanisms research
- MicroRNA in disease regulation
Papers in
-
- MicroRNA in disease regulation 4
- Co-authors
- Lihong Peng (2 shared papers)Jingyan Lin (5 shared papers)Guangyi Liu (1 shared paper)Zhao Wang (1 shared paper)Huang Li (1 shared paper)Xiongfei Tian (1 shared paper)Liqian Zhou (1 shared paper)Jican Dai (3 shared papers)
In The Last Decade
Feixiang Wang
37 papers receiving 302 citations
Peers
Comparison fields: 5 of 81
- Urology 25
- Cancer Research 37
- Psychiatry and Mental health 27
- Reproductive Medicine 15
- Molecular Biology 103
Countries citing papers authored by Feixiang Wang
This map shows the geographic impact of Feixiang Wang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Feixiang Wang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Feixiang Wang more than expected).
Fields of papers citing papers by Feixiang Wang
This network shows the impact of papers produced by Feixiang Wang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Feixiang Wang. The network helps show where Feixiang Wang may publish in the future.
Co-authors
The 25 scholars most cited alongside Feixiang Wang, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 40 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2022 | 74 | |
| 2 | 2018 | 25 | |
| 3 | 2022 | 21 | |
| 4 | 2020 | 19 | |
| 5 | 2019 | 16 | |
| 6 | 2022 | 13 | |
| 7 | 2022 | 11 | |
| 8 | 2024 | 11 | |
| 9 | 2025 | 10 | |
| 10 | 2024 | 9 | |
| 11 | 2015 | 9 | |
| 12 | 2023 | 8 | |
| 13 | 2023 | 8 | |
| 14 | 2020 | 8 | |
| 15 | 2021 | 8 | |
| 16 | 2018 | 7 | |
| 17 | 2024 | 6 | |
| 18 | 2022 | 5 | |
| 19 | 2019 | 5 | |
| 20 | 2024 | 4 |
About Feixiang Wang
Feixiang Wang is a scholar working on Molecular Biology, Cancer Research, Surgery, Critical Care and Intensive Care Medicine and Cellular and Molecular Neuroscience, having authored 40 papers that have together received 306 indexed citations. Recurring topics across this work include MicroRNA in disease regulation (4 papers), Cerebrospinal fluid and hydrocephalus (3 papers), Urological Disorders and Treatments (3 papers), Neuroinflammation and Neurodegeneration Mechanisms (3 papers), Sexual function and dysfunction studies (3 papers), Conducting polymers and applications (2 papers), Advanced Sensor and Energy Harvesting Materials (2 papers) and Intensive Care Unit Cognitive Disorders (2 papers). The work is most often cited by research in Urology (25 citations), Cancer Research (37 citations), Psychiatry and Mental health (27 citations), Reproductive Medicine (15 citations) and Molecular Biology (103 citations). Feixiang Wang has collaborated with scholars based in China, Hong Kong and Spain. Frequent co-authors include Lihong Peng, Jingyan Lin, Guangyi Liu, Zhao Wang, Huang Li, Xiongfei Tian, Liqian Zhou, Jican Dai, Li Wang and Wenzhong Zheng. Their work appears in journals such as Asian Journal of Andrology, Frontiers in Pharmacology, Molecular Biology Reports, Cell Death Discovery and BMC Geriatrics.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.